论文部分内容阅读
肺癌是目前发病率和病死率最高的恶性肿瘤之一,其治疗更是人们关注的焦点。近年来,随着对肺癌分子生物学行为研究的不断深入,肺癌的分子靶向治疗逐渐受到了人们的重视,目前已经发现了多个有应用前途的特异性治疗靶点,其中以表皮生长因子受体(EGFR)最受关注。2003年.世界上第一个表皮生长因子受体拮抗剂吉非替尼(Gefitinib.商品名Iressa)获得FDA的批准在美国上市.给传统方案化疗失败的晚期非小细胞肺癌带来了新的治疗希望。但是,临床研究的结果表明,作为非小细胞肺癌的三线治疗药物,吉非替尼的总体有效率仅10％-15％,美国近期完成的一项大规模临床研究(共涉及1700例肺癌患者)的结果也显示,吉非替尼治疗组的生存期与安慰剂对照组并无显著差别,这给表皮生长因
Lung cancer is currently one of the highest morbidity and mortality of malignant tumors, the treatment is more people’s attention. In recent years, with the further research on the molecular biology of lung cancer, molecular targeted therapy of lung cancer has gradually attracted people’s attention. So far, a number of specific therapeutic targets have been found, of which epidermal growth factor Receptor (EGFR) the most attention. 2003. The world’s first epidermal growth factor receptor antagonist Gefitinib (Iressa) was approved by the FDA for approval in the United States, bringing a new paradigm to advanced non-small cell lung cancer that has failed traditional chemotherapy regimens Hope of treatment. However, the results of clinical studies show that the overall efficacy of gefitinib as a third-line treatment for non-small cell lung cancer is only 10% -15%. A large-scale clinical study recently completed by the United States (involving 1,700 lung cancer patients ) Also showed that the survival of gefitinib treatment group and placebo control group did not differ significantly, which gives epidermal growth factor